Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 284825106 since 12/18/2024, largest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Orbimed Advisors LLC
13D
|
11.0% |
9/25/2026
Event 9/21/2026
|
|
| Orbimed Advisors LLC | 11.0% | ||
| Orbimed Capital GP VII LLC | 8.2% | ||
| OrbiMed Genesis GP LLC | 2.8% | ||
|
Westlake BioPartners Fund I, L.P.
13G
|
10.1% |
10/29/2026
Event 9/30/2026
|
|
| Westlake BioPartners Fund I, L.P. | 5.6% | ||
| Westlake BioPartners GP I, LLC | 5.6% | ||
| Westlake BioPartners Fund II, L.P. | 4.5% | ||
| Westlake BioPartners GP II, LLC | 4.5% | ||
| Dr. Beth C. Seidenberg | 10.1% | ||
|
Redmile Group, LLC
13G
|
8.7% |
9/28/2026
Event 9/21/2026
|
|
| Redmile Group, LLC | 8.7% | ||
| Jeremy C. Green | 8.7% | ||
| Redmile Biopharma Investments II, L.P. | 7.6% | ||
|
LSP 7 Cooperatief U.A.
13G
|
6.0% |
9/28/2026
Event 9/21/2026
|
|
| LSP 7 Cooperatief U.A. | 6.0% | ||
| LSP 7 Management B.V. | 6.0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 21.1 k | $237 k |